MUC1 expression and anti-MUCI serum immune response in head and neck squamous cell carcinoma (HNSCC): A multivariate analysis

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Rabassa, Martín E ^a   Croce, María V ^a   Pereyra, Adrián ^a   Segal Eiras, Amada ^a  

^a UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MACROGOL; MONOCLONAL ANTIBODY; MUCIN 1; POLYCLONAL ANTIBODY; PROTEIN A; PROTEIN ANTIBODY; SEPHAROSE;

ADULT; ADVANCED CANCER; AFFINITY CHROMATOGRAPHY; AGED; ANALYSIS OF VARIANCE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUTH TUMOR; MULTIVARIATE ANALYSIS; PHARYNX CARCINOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRINCIPAL COMPONENT ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TUMOR CELL; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNE SERA; MALE; MIDDLE AGED; MUCIN-1; MUCINS; MULTIVARIATE ANALYSIS;

EID: 33750727658     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-253     Document Type: Article

References (44)

1. Döbrössy L: Epidemiology of head and neck cancer: magnitude of the problem. Cancer and Metastasis Reviews 2005, 24:9-17.
2. Shermann CD Jr: Cancer of the head and neck. In Manual of Clinical Oncology UICC, Springer; 1990.
3. International Agency for research in Cancer, GLOBOCAN 2002 [http://www-dep.iarc.fr]
4. Stewart B, Kleihues P, editors: World cancer report. Lyon: IARC Press; 2003.
5. Dabelsteen E, Gao S: ABO blood-group antigens in oral cancer. J Dent Res 2005, 84:21-8.
6. Croce MV, Price MR, Segal-Eiras A: Detection and isolation of MUC1 mucin from larynx squamous cell carcinoma. Pathol Oncol Res 2000, 6:93-9.
7. Croce MV, Rabassa ME, Price MR, Segal-Eiras A: MUC1 mucin and carbohydrate associated antigens as tumor markers in head and neck squamous cell carcinoma. Pathol Oncol Res 2001, 7:284-91.
8. Croce MV, Rabassa ME, Pereyra A, Segal-Eiras A: Influence of sialic acid removal on MUC1 antigenic reactivity in head and neck carcinoma. Pathol Oncol Res 2005, 11:74-81.
9. Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D, Smith M: MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 2002, 7:209-21.
10. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ: Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994, 54:2856-60.
11. von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, Verstraeten AA, Litvinov SV, van Kamp GJ, Meijer S, Vermorken J, Hilgers J: Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur J Cancer 1996, 32A:1325-31.
12. Croce MV, Isla-Larrain MT, Demichelis SO, Gori JR, Price MR, Segal-Eiras A: Tissue and serum MUC1 mucin detection in breast cancer patients. Breast Cancer Res Treat 2003, 81:195-207.
13. Price MR, Pugh JA, Hudecz F, Griffiths W, Jacobs E, Symonds IM, Clarke AJ, Chan WC, Baldwin RW: C595 - a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas. Br J Cancer 1990, 61:681-6.
14. Croce MV, Isla-Larrain MT, Remes-Lenicov F, Colussi AG, Lacunza E, Kim KC, Gendler SJ, Segal-Eiras A: MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue. Histol Histopathol 2006, 21:849-55.
15. Croce MV, Isla-Larrain MT, Rua CE, Rabassa ME, Gendler SJ, Segal-Eiras A: Patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer. J Histochem Cytochem 2003, 51:781-8.
16. Feickert H, Anger B, Cordó-Cardo C, Lloyd K: Cell-surface antigens of human tumors detected by mouse monoclonal antibodies: definition of blood-group- and non-blood-group-related antigenic systems. Int J Cancer 1990, 46:1007-1013.
17. Renkonen J, Paavonen T, Renkonen R: Endothelial and epithelial expression of sialyl Lewis(x) and sialyl Lewis(a) in lesions of breast carcinoma. Int J Cancer 1997, 74:296-300.
18. Luna-More S, Rius F, Weil B, Jimenez A, Bautista MD, Perez-Mellado A: EMA: a differentiation antigen related to node metastatic capacity of breast carcinomas. Pathol Res Pract 2001, 197:419-25.
19. Croce MV, Price MR, Segal-Eiras A: Expression of monoclonal-antibody-defined antigens in fractions isolated from human breast carcinomas and patients' serum. Cancer Immunol Immunother 1995, 40:132-7.
20. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-5.
21. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979, 76:4350-4.
22. Von Mensdorff-Pouilly S, Gouretvich MM, Kenemans P: An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumor Biol 1989:186-195.
23. Croce MV, Isla-Larrain MT, Capafons A, Price MR, Segal-Eiras A: Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women. Breast Cancer Res Treat 2001, 69:1-11.
24. Wang H, Lillehoj EP, Kim KC: Identification of four sites of stimulated tyrosine phosphorylation in the MUC1 cytoplasmic tail. Biochem Biophys Res Commun 2003, 310:341-6.
25. Zrihan-Licht S, Baruch A, Elroy-Stein O, Keydar I, Wreschner DH: Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins. Cytokine receptor-like molecules. FEBS Lett 1994, 356:130-6.
26. Pandey P, Kharbanda S, Kufe D: Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res 1995, 55:4000-3.
27. Yamamoto M, Bharti A, Li Y, Kufe D: Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. J Biol Chem 1997, 272:12492-4.
28. Schroeder JA, Thompson MC, Gardner MM, Gendler SJ: Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem 2001, 276:13057-64.
29. Wreschner DH, Hareuveni M, Tsarfaty I, Smorodinsky N, Horev J, Zaretsky I, Kotkes P, Weiss M, Lathe R, Dion AS, Keydar I: Human epithelial tumor antigen cDNA sequences - differential splicing may generate multiple protein forms. Eur J Biochem 1990, 189:463-73.
30. Zrihan-Licht S, Vos HL, Baruch A, Elroy-Stein O, Sagiv D, Keydar I, Hilkens J, Wreschner DH: Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue. Eur J Biochem 1994, 224:787-95.
31. Obermair A, Schmid BC, Stimpfl M, Fasching B, Preyer O, Leodolter S, Crandon AJ, Zeillinger R: Novel MUC1 splice variants are expressed in cervical carcinoma. Gynecol Oncol 2001, 83:343-7.
32. Agrawal B, Reddish MA, Longenecker BM: In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J Immunol 1996, 157:2089-95.
33. Petrarca C, Rughetti A, Rahimi H, D'Agostini F, Turchi V, Apollonj Ghetti C, Scambia G, Frati L, Nuti M: Human antibodies against the polymorphic epithelial mucin in ovarian cancer patients recognise a novel sequence in the tandem repeat region. Eur J Cancer 1996, 32A:2155-63.
34. Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y: Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 2003, 103:97-100.
35. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J: Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000, 18:574-83.
36. Vlock DR, Scalise D, Schwartz DR, Richter DE, Krause CJ, Baker SR, Carey TE: Incidence of serum antibody reactivity to autologous head and neck cancer cell lines and augmentation of antibody reactivity following acid dissociation and ultrafiltration. Cancer Res 1989, 49:1361-5.
37. Yamanaka N, Himi T, Harabuchi Y, Hoki K, Kataura A: Soluble immune complexes and squamous cell carcinoma-related antigens in patients with head and neck cancer. Cancer 1988, 62:1932-8.
38. Wolf GT, Wolfe RA: Circulating immune complexes in patients with nasopharyngeal carcinoma. Laryngoscope 1990, 100:302-8.
39. Das TK, Aziz M, Rattan A, Sherwani R: Prognostic significance of circulating immune complexes in malignant tumours of head and neck. J Indian Med Assoc 1995, 93:3-7.
40. Litvinov SV, Hilkens J: The epithelial sialomucin, episialin, is sialylated during recycling. J Biol Chem 1993, 268:21364-71.
41. Ligtenberg MJ, Vos HL, Gennissen AM, Hilkens J: Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem 1990, 265:5573-8.
42. Williams CJ, Wreschner DH, Tanaka A, Tsarfaty I, Keydar I, Dion AS: Multiple protein forms of the human breast tumor-associated epithelial membrane antigen (EMA) are generated by alternative splicing and induced by hormonal stimulation. Biochem Biophys Res Commun 1990, 170:1331-8.
43. Levitin F, Stern O, Weiss M, Gil-Henn C, Ziv R, Prokocimer Z, Smorodinsky NI, Rubinstein DB, Wreschner DH: The MUC1 SEA module is a self-cleaving domain. J Biol Chem 2005, 280:33374-86.
44. Wen Y, Caffrey TC, Wheelock MJ, Johnson KR, Hollingsworth MA: Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J Biol Chem 2003, 278:38029-39.